



May 31, 2019

Web Announcement 1905

Drug Use Review (DUR) Board Approves Changes Effective June 3, 2019

The Nevada Medicaid Drug Use Review (DUR) Board met on October 18, 2018, and January 24, 2019, and voted to adopt the following changes. These changes are effective June 3, 2019.

Drug Class/Program	Changes
Immunomodulator Drugs	Prior authorization added for Ilumya® (tildrakizumab), Inflectra® (infliximab), Olumiant® (baricitinib), Otezla® (apremilast), Renflexis® (infliximab) and Taltz® (ixekizumab)
Anti-Migraine Medications – Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitors	Prior authorization criteria added
Short-Acting Bronchodilators	Prior authorization criteria added including quantity limits
Opioids Prescribed to Under Age 18	Prior authorization criteria added
Compounded Medications	Updated prior authorization criteria to require prior authorization on all compounded products
Oral Oncology Agents	Prior authorization criteria added
Pulmonary Hypertension Agents	Prior authorization criteria added
Anticonvulsants	Prior authorization criteria added for Epidiolex® (cannabidiol)